RxDoctor Payments Data

Nataliya Holmes, MD

Family Medicine · Mililani, HINPI 1154785368

Payments from drug & device makers

$855in general payments, 2019–2025

Across 19 payments — averaging $44.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$273
  • Novo Nordisk$234
  • Madrigal Pharmaceuticals$121
  • Exact Sciences$50
  • Amarin Pharma, Inc.$37
  • Gilead$30
  • plus $108 from 5 others

What the payments were for

  • Food & beverage$855100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$855 in reported general payments places this provider in the 70th percentile of 376 family medicine providers in Hawaii.

See all family medicine providers in Hawaii

Medicare billing

Part B allowed, 2024
$38,853
Medicare patients
157
Services billed
382

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin23$38,963
EliquisApixaban14$23,527
TrulicityDulaglutide18$19,585
VascepaIcosapent Ethyl20$16,053
Atorvastatin Calcium321$9,218
Irbesartan151$6,321
Ezetimibe41$2,734
Losartan Potassium143$2,407
Rosuvastatin Calcium50$2,025
Levalbuterol Tartrate HfaLevalbuterol Tartrate22$1,883
Amlodipine Besylate154$1,844
Wixela InhubFluticasone Propion/Salmeterol13$1,484
Duloxetine Hcl17$1,442
Omeprazole30$1,408
Montelukast Sodium20$1,221

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$19$23,52714 claims
Lilly USA, LLCTrulicity$20$19,58518 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 376 family medicine providers in Hawaii.

Other family medicine in Mililani

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →